NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. ("Candel") (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the pricing of an underwritten public offering of 10,000,001 shares of its common stock at a price to the public of $6.00 per share and pre-funded warrants to purchase up to an aggregate of 3,333,333 shares of its common stock at a price to the public of $5.99 ...

NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the launch of an underwritten public offering of $80 million of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All shares of common stock and pre-funded warrants to be sold in th ...

Shares of Candel Therapeutics (CADL) surged 68.1% on Wednesday after the company reported superior efficacy of CAN-2409, an investigational adenovirus immunotherapy candidate, compared to standard of care (SOC) radiation therapy alone in a late-stage study to treat prostate cancer.The phase III study enrolled intermediate-to-high-risk, localized prostate cancer patients who either received the combination therapy of CAN-2409+prodrug (valacyclovir)+SOC or SOC alone. The study met its primary endpoint, demons ...

I have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wr ...

Candel Therapeutics Inc (NASDAQ:CADL) is soaring today, up 164% at $12.17 at last glance and earlier hitting a three-year high of $14.60, after the biotech company's prostate cancer immunotherapy treatment, CAN-2409, met its goal in a late-stage study. Combined with radiation therapy, it significantly improved the time patients lived without signs or symptoms of the cancer. On the charts, CADL inched above its mid-May peak to mark its highest levels since September 2021. And before today, the 320-day moving ...

On Wednesday, Candel Therapeutics, Inc. CADL announced results from a phase 3 trial of CAN-2409 viral immunotherapy in intermediate-to-high-risk, localized prostate cancer patients. The trial met its primary endpoint and demonstrated statistically significant improvement in disease-free survival in patients who received CAN-2409 plus the prodrug (valacyclovir) combined with the standard of care compared to the standard of care alone.CAN-2409, when administered with valacyclovir, is designed to induce immuno ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Core Insights - Candel Therapeutics Inc is focused on developing innovative cancer therapies, particularly for prostate cancer, with its lead candidate CAN-2409 aiming to shift treatment paradigms for non-metastatic, localized prostate cancer [1][2] - The treatment landscape for early-stage prostate cancer has seen little progress in over 20 years, with current options limited and often burdensome for patients [2][4] - CAN-2409 is designed to provide a well-tolerated treatment option that extends progression-free survival and delays the need for radical treatments [4][5] Group 1: Prostate Cancer Treatment Landscape - Prostate cancer is one of the most common cancers in men, with high survival rates for early-stage disease, yet treatment options remain stagnant [2] - Current treatments, such as radical prostatectomy and radiotherapy, come with significant side effects, leading many patients to choose active surveillance [2][3] - Approximately 40% of low-risk and 10% of intermediate-risk prostate cancer patients opt for active surveillance due to the risks associated with radical therapies [3] Group 2: CAN-2409 Development and Trials - CAN-2409 is a viral immunotherapy that specifically targets tumor cells, creating a vaccination-like effect to stimulate a targeted immune response [5] - A phase 2b clinical trial involving 187 patients is set to read out in December, aiming to determine if CAN-2409 can shift the current treatment paradigm [4] - CAN-2409 is also being evaluated in a phase 3 clinical trial for intermediate-to-high risk prostate cancer patients receiving standard radiotherapy, with results expected in December [4] Group 3: Broader Applications and Future Therapies - Candel is also developing CAN-3110, a therapy for glioblastoma and other solid tumors, which has shown promising results in clinical trials [6][8] - CAN-3110 involves injecting a modified herpes simplex virus directly into tumors, leading to a doubling of expected survival in patients with recurrent high-grade glioma [8] - The company is exploring the potential of CAN-3110 in other cancers, including melanoma and triple-negative breast cancer, based on preclinical studies demonstrating anti-tumor efficacy [8] Group 4: Funding and Strategic Partnerships - Candel is currently funded through the first quarter of next year, with a focus on delivering key clinical data to support future financing efforts [9] - Positive data from prostate cancer trials could attract strong interest from pharmaceutical companies for strategic partnerships [9] - The company emphasizes the importance of aligning any potential deals with its long-term vision to maximize patient impact [9]

In the biopharmaceutical world, where innovation and breakthroughs often dominate headlines, a fundamental question is frequently overlooked: are we truly listening to patients? For Paul Peter Tak CEO of Candel Therapeutics Inc (NASDAQ:CADL), the answer has shaped a career rooted in both scientific discovery and personal resilience. As Candel prepares to unveil pivotal data from its prostate cancer clinical trials, Dr Tak reflects on the crucial role of embedding patient voices in the heart of medical innov ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government. S ...